FDA
-
-
-
-
-
-
-
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
-
-
-
-
-
-
-
Foamix (FOMX) Announces AMZEEQ Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
-
-
-
-
-
-
-
UPDATE: Menlo Therapeutics (MNLO) Announces Merger Agreement with Foamix Pharmaceuticals Ltd. (FOMX)
-
-
-
-
-
-
-
Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103
-
-
-
-
-
-
-
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
-
-
-
-
-
-
-
Foamix (FOMX) Announces Issuance of New U.S. Patent Covering A Method of Treating Acne
-
-
-
-
-
-
-
Foamix (FOMX) Reports Publication of Phase 3 FMX101 Acne Study
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

